Initiate daclizumab in restricted groups of patients with limited treatment options and closely monitor liver function.
Closely monitor patients for opportunistic infections as well as cardiac, neurological, and respiratory adverse events.
Consider the benefit of treatment with nivolumab or pembrolizumab versus the risk of possible organ transplant rejection for each patient.
Advise patients to report any ear pain, discharge from ear, or an ear infection during denosumab treatment.
Advise patients not to apply brimonidine gel to irritated or damaged skin.
Sale and supply of these products should be done under supervision of pharmacist or suitably trained pharmacy staff.
Advise patients to discontinue treatment immediately if episodes of depressive illness and suicidal thoughts are reported.
Illicit drug reaction reporting form made available for healthcare professionals,
9 fatalities have been reported so far.
Increased risk for depression and suicidality in apremilast users.
